You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Kisunla® (donanemab-azbt) be used in patients receiving treatments with other therapeutic antibodies?
Based on the pharmacokinetic characteristics of donanemab, drug interactions with therapeutic antibodies are not expected. Donanemab clinical studies did not explicitly exclude concomitant use of therapeutic antibodies.
See important safety information, including boxed warning, in the attached prescribing information.
Combination Use With Therapeutic Antibodies Has Not Been Studied
The placebo-controlled studies did not explicitly exclude concomitant use of therapeutic monoclonal antibodies.1,2
However, these studies excluded patients from participation if they had current
Drug Interaction Studies Were Not Conducted
Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody and is expected to be degraded by proteolytic enzymes in the same manner as endogenous IgG.3
As such, donanemab is not expected to
- inhibit metabolic or induce enzymatic pathways
- be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, or
- produce any active metabolites.4
No formal drug interaction studies were performed with donanemab. No pharmacokinetic drug interactions are expected based on the characteristics of donanemab.4
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Mintun MA, Lo AC, Evans CD, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691-1704. https://doi.org/10.1056/NEJMoa2100708
2Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. https://doi.org/10.1001/jama.2023.13239
3Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
4Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: April 22, 2026